Co-Founder And Ceo
CurrentTranscend Therapeutics discovers, develops, and delivers next-generation psychoactive medicines to work toward a world in which people no longer suffer from neuropsychiatric disease. Transcend focuses on developing medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. Transcend’s leadership team includes the first scientist to receive federal funding for clinical psychedelic research in 54 years drug, development executives with pivotal contributions to >20 FDA approvals and seven major biopharma exits totaling $4 billion in combined value. We are backed by AlleyCorp, an incubator and venture capital fund that has founded some of the most transformative companies in New York, including MongoDB, Business Insider, Gilt Groupe, Zola, Nomad Health, and many others.
